| The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review L Barbier, HC Ebbers, P Declerck, S Simoens, AG Vulto, I Huys Clinical Pharmacology & Therapeutics 108 (4), 734-755, 2020 | 128 | 2020 |
| The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars L Barbier, P Declerck, S Simoens, P Neven, AG Vulto, I Huys British journal of cancer 121 (3), 199-210, 2019 | 73 | 2019 |
| European stakeholder learnings regarding biosimilars: part I—improving biosimilar understanding and adoption L Barbier, S Simoens, AG Vulto, I Huys BioDrugs 34 (6), 783-796, 2020 | 43 | 2020 |
| European stakeholder learnings regarding biosimilars: part II—improving biosimilar use in clinical practice L Barbier, S Simoens, AG Vulto, I Huys BioDrugs 34 (6), 797-808, 2020 | 36 | 2020 |
| Off-patent biologicals and biosimilars tendering in Europe—a proposal towards more sustainable practices L Barbier, S Simoens, C Soontjens, B Claus, AG Vulto, I Huys Pharmaceuticals 14 (6), 499, 2021 | 25 | 2021 |
| Regulatory information and guidance on biosimilars and their use across Europe: a call for strengthened one voice messaging L Barbier, A Mbuaki, S Simoens, P Declerck, AG Vulto, I Huys Frontiers in Medicine 9, 820755, 2022 | 22 | 2022 |
| Interchangeability of biosimilars: overcoming the final hurdles L Barbier, AG Vulto Drugs 81, 1897-1903, 2021 | 15 | 2021 |
| Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians L Barbier, Y Vandenplas, S Simoens, P Declerck, AG Vulto, I Huys Journal of Pharmaceutical Policy and Practice 14 (1), 53, 2021 | 10 | 2021 |
| How to balance valuable innovation with affordable access to medicines in Belgium? S Simoens, K Abdallah, L Barbier, TB Lacosta, A Blonda, E Car, ... Frontiers in Pharmacology 13, 960701, 2022 | 9 | 2022 |
| Perceptions about biosimilar medicines among Belgian patients in the ambulatory care Y Vandenplas, L Barbier, S Simoens, P Van Wilder, AG Vulto, I Huys Frontiers in Pharmacology 12, 789640, 2022 | 7 | 2022 |
| PNS151 The role of regulatory guidance and information dissemination for biosimilar medicines-the perspective of healthcare professionals and industry L Barbier, A Mbuaki, S Simoens, A Vulto, I Huys Value in Health 22, S786-S787, 2019 | 7 | 2019 |
| Community pharmacists' preparedness for substituting biologics and dispensing biosimilars–Lessons learned from a multinational survey I Arnet, M Verbeek, BA Anna, L Barbier, R Clifford, C Eickhoff, ... Exploratory Research in Clinical and Social Pharmacy 4, 100084, 2021 | 5 | 2021 |
| Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group MA Hogervorst, R Vreman, I Heikkinen, I Bagchi, I Gutierrez-Ibarluzea, ... International journal of technology assessment in health care 39 (1), e40, 2023 | 4 | 2023 |
| Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking L Barbier, S Simoens, P Declerck, AG Vulto, I Huys Frontiers in Pharmacology 13, 821616, 2022 | 4 | 2022 |
| Informing a European guidance framework on electronic informed consent in clinical research: a qualitative study E De Sutter, P Borry, I Huys, L Barbier BMC Health Services Research 23 (1), 181, 2023 | 3 | 2023 |
| How to select a best-value biological medicine? A practical model to support hospital pharmacists L Barbier, Y Vandenplas, N Boone, I Huys, R Janknegt, AG Vulto American Journal of Health-System Pharmacy 79 (22), 2001-2011, 2022 | 3 | 2022 |
| How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action R Janssens, L Barbier, M Muller, I Cleemput, I Stoeckert, C Whichello, ... Frontiers in Pharmacology 14, 1192770, 2023 | 2 | 2023 |
| Compulsory licensing for expensive medicines E van Zimmeren, T Minssen, L Paemel, W Van Dyck, J Luyten, ... KCE Reports 356 356, 2022 | 2 | 2022 |
| When Will American Patients Start Benefitting From Biosimilars? AG Vulto, L Barbier Mayo Clinic Proceedings 97 (6), 1044-1047, 2022 | 2 | 2022 |
| Effectively educating clinicians and patients on biosimilars across europe: getting the right message across L Barbier, T Barcina Lacosta, Y Vandenplas Biosimilar Dev, 2021 | 2 | 2021 |
